1 Anti-Emetic Drug Market Overview

• 1.1 Product Overview and Scope of Anti-Emetic Drug
• 1.2 Anti-Emetic Drug Segment by Type
  • 1.2.1 Global Anti-Emetic Drug Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Oral
  • 1.2.3 Injection
  • 1.2.4 Others
• 1.3 Anti-Emetic Drug Segment by Application
  • 1.3.1 Anti-Emetic Drug Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Home Care
  • 1.3.5 Others
• 1.4 Global Anti-Emetic Drug Market Size Estimates and Forecasts
  • 1.4.1 Global Anti-Emetic Drug Revenue 2016-2027
  • 1.4.2 Global Anti-Emetic Drug Sales 2016-2027
  • 1.4.3 Anti-Emetic Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Anti-Emetic Drug Market Competition by Manufacturers

• 2.1 Global Anti-Emetic Drug Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Anti-Emetic Drug Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Anti-Emetic Drug Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Anti-Emetic Drug Manufacturing Sites, Area Served, Product Type
• 2.5 Anti-Emetic Drug Market Competitive Situation and Trends
  • 2.5.1 Anti-Emetic Drug Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Anti-Emetic Drug Players Market Share by Revenue
  • 2.5.3 Global Anti-Emetic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Anti-Emetic Drug Retrospective Market Scenario by Region

• 3.1 Global Anti-Emetic Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Anti-Emetic Drug Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Anti-Emetic Drug Market Facts & Figures by Country
  • 3.3.1 North America Anti-Emetic Drug Sales by Country
  • 3.3.2 North America Anti-Emetic Drug Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Anti-Emetic Drug Market Facts & Figures by Country
  • 3.4.1 Europe Anti-Emetic Drug Sales by Country
  • 3.4.2 Europe Anti-Emetic Drug Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Anti-Emetic Drug Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Anti-Emetic Drug Sales by Region
  • 3.5.2 Asia Pacific Anti-Emetic Drug Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Anti-Emetic Drug Market Facts & Figures by Country
  • 3.6.1 Latin America Anti-Emetic Drug Sales by Country
  • 3.6.2 Latin America Anti-Emetic Drug Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Anti-Emetic Drug Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Anti-Emetic Drug Sales by Country
  • 3.7.2 Middle East and Africa Anti-Emetic Drug Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Anti-Emetic Drug Historic Market Analysis by Type

• 4.1 Global Anti-Emetic Drug Sales Market Share by Type (2016-2021)
• 4.2 Global Anti-Emetic Drug Revenue Market Share by Type (2016-2021)
• 4.3 Global Anti-Emetic Drug Price by Type (2016-2021)

5 Global Anti-Emetic Drug Historic Market Analysis by Application

• 5.1 Global Anti-Emetic Drug Sales Market Share by Application (2016-2021)
• 5.2 Global Anti-Emetic Drug Revenue Market Share by Application (2016-2021)
• 5.3 Global Anti-Emetic Drug Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Merck
  • 6.1.1 Merck Corporation Information
  • 6.1.2 Merck Description and Business Overview
  • 6.1.3 Merck Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Merck Product Portfolio
  • 6.1.5 Merck Recent Developments/Updates
• 6.2 Novartis
  • 6.2.1 Novartis Corporation Information
  • 6.2.2 Novartis Description and Business Overview
  • 6.2.3 Novartis Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Novartis Product Portfolio
  • 6.2.5 Novartis Recent Developments/Updates
• 6.3 Glenmark Pharmaceuticals
  • 6.3.1 Glenmark Pharmaceuticals Corporation Information
  • 6.3.2 Glenmark Pharmaceuticals Description and Business Overview
  • 6.3.3 Glenmark Pharmaceuticals Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Glenmark Pharmaceuticals Product Portfolio
  • 6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
• 6.4 F. Hoffmann-La Roche
  • 6.4.1 F. Hoffmann-La Roche Corporation Information
  • 6.4.2 F. Hoffmann-La Roche Description and Business Overview
  • 6.4.3 F. Hoffmann-La Roche Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 F. Hoffmann-La Roche Product Portfolio
  • 6.4.5 F. Hoffmann-La Roche Recent Developments/Updates
• 6.5 Heron Therapeutics
  • 6.5.1 Heron Therapeutics Corporation Information
  • 6.5.2 Heron Therapeutics Description and Business Overview
  • 6.5.3 Heron Therapeutics Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Heron Therapeutics Product Portfolio
  • 6.5.5 Heron Therapeutics Recent Developments/Updates
• 6.6 Kyowa Kirin
  • 6.6.1 Kyowa Kirin Corporation Information
  • 6.6.2 Kyowa Kirin Description and Business Overview
  • 6.6.3 Kyowa Kirin Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Kyowa Kirin Product Portfolio
  • 6.6.5 Kyowa Kirin Recent Developments/Updates
• 6.7 Aurobindo Pharma
  • 6.6.1 Aurobindo Pharma Corporation Information
  • 6.6.2 Aurobindo Pharma Description and Business Overview
  • 6.6.3 Aurobindo Pharma Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Aurobindo Pharma Product Portfolio
  • 6.7.5 Aurobindo Pharma Recent Developments/Updates
• 6.8 Mylan
  • 6.8.1 Mylan Corporation Information
  • 6.8.2 Mylan Description and Business Overview
  • 6.8.3 Mylan Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Mylan Product Portfolio
  • 6.8.5 Mylan Recent Developments/Updates
• 6.9 Hikma
  • 6.9.1 Hikma Corporation Information
  • 6.9.2 Hikma Description and Business Overview
  • 6.9.3 Hikma Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Hikma Product Portfolio
  • 6.9.5 Hikma Recent Developments/Updates
• 6.10 Akorn
  • 6.10.1 Akorn Corporation Information
  • 6.10.2 Akorn Description and Business Overview
  • 6.10.3 Akorn Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Akorn Product Portfolio
  • 6.10.5 Akorn Recent Developments/Updates
• 6.11 Dr. Reddy’s Laboratories
  • 6.11.1 Dr. Reddy’s Laboratories Corporation Information
  • 6.11.2 Dr. Reddy’s Laboratories Anti-Emetic Drug Description and Business Overview
  • 6.11.3 Dr. Reddy’s Laboratories Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Dr. Reddy’s Laboratories Product Portfolio
  • 6.11.5 Dr. Reddy’s Laboratories Recent Developments/Updates
• 6.12 Cipla
  • 6.12.1 Cipla Corporation Information
  • 6.12.2 Cipla Anti-Emetic Drug Description and Business Overview
  • 6.12.3 Cipla Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Cipla Product Portfolio
  • 6.12.5 Cipla Recent Developments/Updates
• 6.13 Fresenius Kabi
  • 6.13.1 Fresenius Kabi Corporation Information
  • 6.13.2 Fresenius Kabi Anti-Emetic Drug Description and Business Overview
  • 6.13.3 Fresenius Kabi Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 Fresenius Kabi Product Portfolio
  • 6.13.5 Fresenius Kabi Recent Developments/Updates
• 6.14 Wockhardt
  • 6.14.1 Wockhardt Corporation Information
  • 6.14.2 Wockhardt Anti-Emetic Drug Description and Business Overview
  • 6.14.3 Wockhardt Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 Wockhardt Product Portfolio
  • 6.14.5 Wockhardt Recent Developments/Updates
• 6.15 Sun Pharmaceutical Industries
  • 6.15.1 Sun Pharmaceutical Industries Corporation Information
  • 6.15.2 Sun Pharmaceutical Industries Anti-Emetic Drug Description and Business Overview
  • 6.15.3 Sun Pharmaceutical Industries Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Sun Pharmaceutical Industries Product Portfolio
  • 6.15.5 Sun Pharmaceutical Industries Recent Developments/Updates
• 6.16 Teva Pharmaceutical
  • 6.16.1 Teva Pharmaceutical Corporation Information
  • 6.16.2 Teva Pharmaceutical Anti-Emetic Drug Description and Business Overview
  • 6.16.3 Teva Pharmaceutical Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.16.4 Teva Pharmaceutical Product Portfolio
  • 6.16.5 Teva Pharmaceutical Recent Developments/Updates
• 6.17 Pfizer
  • 6.17.1 Pfizer Corporation Information
  • 6.17.2 Pfizer Anti-Emetic Drug Description and Business Overview
  • 6.17.3 Pfizer Anti-Emetic Drug Sales, Revenue and Gross Margin (2016-2021)
  • 6.17.4 Pfizer Product Portfolio
  • 6.17.5 Pfizer Recent Developments/Updates

7 Anti-Emetic Drug Manufacturing Cost Analysis

• 7.1 Anti-Emetic Drug Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Anti-Emetic Drug
• 7.4 Anti-Emetic Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Anti-Emetic Drug Distributors List
• 8.3 Anti-Emetic Drug Customers

9 Anti-Emetic Drug Market Dynamics

• 9.1 Anti-Emetic Drug Industry Trends
• 9.2 Anti-Emetic Drug Growth Drivers
• 9.3 Anti-Emetic Drug Market Challenges
• 9.4 Anti-Emetic Drug Market Restraints

10 Global Market Forecast

• 10.1 Anti-Emetic Drug Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Anti-Emetic Drug by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Anti-Emetic Drug by Type (2022-2027)
• 10.2 Anti-Emetic Drug Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Anti-Emetic Drug by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Anti-Emetic Drug by Application (2022-2027)
• 10.3 Anti-Emetic Drug Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Anti-Emetic Drug by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Anti-Emetic Drug by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Oral
Injection
Others

Segment by Application
Hospital
Clinic
Home Care
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Merck
Novartis
Glenmark Pharmaceuticals
F. Hoffmann-La Roche
Heron Therapeutics
Kyowa Kirin
Aurobindo Pharma
Mylan
Hikma
Akorn
Dr. Reddy’s Laboratories
Cipla
Fresenius Kabi
Wockhardt
Sun Pharmaceutical Industries
Teva Pharmaceutical
Pfizer